Loxo Oncology, Inc. SEC Filings

Filed On	Filing
14 Feb 2020	SC 13G/A
08 Jan 2020	SEC SCHEDULE 13G
25 Feb 2019	15-12B
21 Feb 2019	EFFECT
15 Feb 2019	POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8
15 Feb 2019	POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8
15 Feb 2019	POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8
15 Feb 2019	POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8
15 Feb 2019	POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8
15 Feb 2019	POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8
15 Feb 2019	POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3
15 Feb 2019	POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3
15 Feb 2019	AMENDMENT NO. 5
15 Feb 2019	SC 14D9/A
15 Feb 2019	AMENDMENT NO. 3 TO SCHEDULE TO
15 Feb 2019	Form 4: Van Naarden Jacob, Chief Operating Officer Returned 19,000 shares to the issuer ($4.47M) · Disposed of 522,969 Employee Stock Option (Right to Buy) (Disposition to Issuer) ($123M)
15 Feb 2019	Form 4: Nanda Nisha, Chief Development Officer Returned 18,896 shares to the issuer ($4.44M) · Disposed of 213,702 Employee Stock Option (Right to Buy) (Disposition to Issuer) ($50.2M)
15 Feb 2019	Form 4: Naider Avi Z., Director Gave 15,000 shares as a gift · Returned 111,843 shares to the issuer ($26.3M) · Disposed of 50,999 Employee Stock Option (Right to Buy) (Disposition to Issuer) ($12M)
15 Feb 2019	25-NSE
15 Feb 2019	Form 4: Mayleben Timothy M, Director Disposed of 30,187 Employee Stock Option (Right to Buy) (Disposition to Issuer) ($7.09M)

Comments